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Timothy M. Wick 
Cell Adhesion 
1. Specific Aims 
A prominent factor contributing to the morbidity and mortality of sickle cell anemia is 
microvascular occlusion by sickle red blood cells. It has been suggested that young sickle red cells 
adhere to microvascular endothelium and delay transit of subsequent cells. This partial impediment 
selectively traps the old, dense, mechanically rigid sickle cells and irreversibly sickled cells; leading 
to complete occlusion, ischemia, and tissue damage. 
Sickle erythrocytes are abnormally adhesive to endothelial cells in vitro. The level of in vitro 
adhesion quantitatively correlates with the clinical severity of sickle cell disease, suggesting that 
adherence may be a determining factor in the clinical variability reported in patients. Adhesion likely 
occurs in the post-capillary venules, where red cells are in close proximity to the endothelium and 
blood-shearing forces opposing adhesion are low. 
We propose to elucidate the mechanism(s) of sickle cell adherence to endothelial cells under 
physiologically relevant flow conditions in vitro. This will be accomplished through studies defined 
by the following specific aims: 
1. Characterize the difference between sickle cell adherence to large-vessel and microvascular 
endothelium by determining the effects of agonists and antagonists on adherence. 
2. Identify plasma factors, including factors released from activated sickle platelets, responsible for 
adherence. 
3. Determine the variability in sickle cell adhesion to endothelial cells from patient to patient and for 
individual patients during crisis and asymptomatic periods. 
4. Contrast the effects of agonists which presumably stimulate endothelial cells, such as thrombin, 
endotoxin, plasmin, histamine, fibrin(ogen), interleukin-1, and tumor necrosis factor on adherence. 
2. Studies and Results 
Methods 
Adherence of washed sickle red blood cells suspended in various media (e.g. plasma, serum-free 
medium, serum-free medium containing purified proteins) to human umbilical vein (1) or human 
dermal microvascular endothelial cell (2) monolayers is measured at a shear stress of 1.0 dyne/cm 2 
 essentially as described in the original application. Present studies are confined to asymptomatic 
patients to determine which parameters are important in adherence. 
Differences between adherence to umbilical vein and microvascular endothelium.  
We have previously reported that high molecular weight von Willebrand factor (vWF) multimers 
promote sickle, but not normal, red cell adhesion to umbilical vein endothelium (1). However, high 
molecular weight vWF multimers only promote low levels of sickle red cell adherence to 
microvascular endothelial cells (Figure 1). In contrast, autologous sickle plasma promotes greater 
sickle cell adherence to microvascular as compared to umbilical vein endothelium (Figure 2). 
Additional studies on 45 patients indicate that plasma-mediated sickle cell adherence to 
microvascular endothelial cells varies over three orders of magnitude (data not shown). 
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()Figure 1. Washed sickle cells were suspended in serum-free Figure 2. Washed sickle cells were suspended in SFM or 
medium (SFM) or SFM containing high molecular weight SFM containing 30% autologous sickle plasma (Plasma). 
Z umbilical vein endothelium was measured at a shear stress 
vWF (HMWvWF) and adherence to microvascular and 
ci) of 1.0 dyne/cm 2. 
z 	
These data suggest that the mechanism of sickle cell adherence to large vessel and 
microvascular endothelium is qualitatively different. Since adherence is likely of clinical significance 
....gol•L' in the microcirculation, we have undertaken additional studies to further characterize plasma- 
14.mediated sickle cells adherence to microvascular endothelium. 
a Plasma factors which promote adherence z 	Additional data indicate that the adhesion promoting components of sickle plasma are greater 
than 100 kDa molecular weight (3 patients, not shown) and that collagen-binding proteins account 
it for 56% of the plasma mediated adherence (11 patients, not shown), suggesting that large adhesive 
proteins (vWF [3], thrombospondin [4], fibronectin [5] all bind to collagen) in sickle plasma account 
for the observed adherence. 
>.Activated Sickle Platelet Supernatant Promotes Sickle Cell Adherence  
More recently, we have become interested in the role of activated platelets in sickle cell 
adherence. To test the hypothesis that activated sickle platelets secrete factors which promote 
Cl) sickle cell adherence, we isolated sickle platelets from platelet-rich plasma and activated them with 
• ■ 0.1U/ml thrombin in SFM (6). The activated sickle platelet supernatant (ASPS) was collected and 
W used as a red cell suspending medium. ASPS promoted high levels of sickle, but only moderate 
V.)„, levels of normal red cell adherence to microvascular endothelium (Figure 3). Preincubation of 
7;k microvascular endothelium with an antibody (OKM5) against the thrombospondin receptor (CD36) 
(7) inhibits 86% of the ASPS-mediated adherence (Figure 4). 
z 	
ASPS-Mediated Sickle Cell Adherence Is Inhibited by Activated Sickle Platelet Supernatant (ASPS) Promotes Sickle 	
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Figure 3. Sickle platelets were isolated, washed, and 
	
Figure 4. Sickle cells were suspended in ASPS and 
activated for 10-min with 0.1U/ml thrombin in a volume of adherence to endothelium preincubated with anti-CD36 
SFM equal to the plasma volume. Sickle or normal red 
	
antibody (OKM5) was compared to antibody-free 
cells were suspended in ASPS and adherence to 	 endothelium. 
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Thrombospondin is stored in platelet a-granules and released upon platelet activation (8). 
The data of Figure 4 indirectly implicate thrombospondin as a factor in ASPS which mediates 
adherence. As shown in Figure 5, purified thrombospondin in SFM promotes 6-fold greater sickle as 
compared to normal red cell adherence to microvascular endothelium (at a plasma concentration of 
thrombospondin). When the suspension concentration of thrombospondin is doubled, adherence 
increases proportionally (Figure 6). 
Purified ihrombospondin Promotes Sickle Red 




Figure 5. Purified thrombospondin at 0.2 µ.g/ml 
rt. concentration promotes higher sickle cell adherence to 
microvascular endothelium. 
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Figure 6. Thrombospondin-mediated sickle cell adherence 










2 	Thrombospondin binds to endothelial cell CD36 (7) and vitronectin (a v i33) receptors (9). 
Z Preincubation of microvascular endothelial cells with anti-CD36 receptor antibody (OKM5, Figure 
7a) or anti-ccv antibody (Figure 7b) inhibits thrombospondin-mediated sickle cell adherence by 96% 
I— and 99%, respectively. 
An11-CD36 Receptor Antibody (OKM6) Inhibits 
TSP-Meddled Sickle Cell Adherence 
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Z Figure 7. Microvascular endothelial cells were preincubated with OKM5 or anti-a y antibody for 1 hour prior to the 
0 adherence assay. OKM5 or anti-a y antibody inhibited 99% or 96% of the thrombospomlin-mediated adherence, respectively. 
-rz An antibody against an endothelial cell epitope not thought to be involved in adherence (MHC Class-1) did not inhibit 
< thrombospondin-mediated sickle cell adherence (data not shown). 
Z 	Finally, for the 28 patients studies to date, the ASPS-mediated adherence levels positively 
I. correlate with patient platelet count (Figure 8). These data suggest that platelet-derived adhesion 
Z factors may participate in adherence in vivo. Additional studies to test this hypothesis are outlined 
• below. 
C) 
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CI 3. Significance 
ZDifferences between adherence to microvascular and umbilical vein endothelium. 
It is clear from our work (1) and that of others (10) that high molecular weight vWF 
Cnmultimers promote sickle cell adherence to venous endothelium. It is likely that vWF-mediated 
_adherence in the post-capillary venules contributes to vessel occlusion characteristic of sickle cell 
Ocrisis. However, our new data indicating that plasma, and not high molecular weight vWF, promotes 
CC sickle cell adherence to microvascular endothelium (which is predominantly capillary endothelium) 
<suggest that capillary adherence mediated by plasma factors might also contribute to adherence. 
M Thus, further characterization of sickle cell adherence to microvascular endothelium potentially will 
.s,refine our knowledge of the pathophysiology of vaso-occlusion. Furthermore, the facts that (i) 
&-patient-to-patient plasma adherence levels vary widely for asymptomatic patients (see above) and 
MOD that for individual patients, plasma-mediated adherence exhibits small longitudinal variation 
iii•m(data not shown) suggests that the level of plasma-mediated adherence might correlate with the 
variability in clinical complications (frequency and severity) in the sickle population. Obviously, we 
need additional data to test this hypothesis and this is one goal of the present grant. 
>1  ctivated Sickle Platelet Supernatant Promotes Sickle Cell Adherence  
Many previous investigators have presented data indicating that the coagulation system is 
(inactivated in sickle patients (see 11 for recent review). These reports have led some to suggest that 
..crisis and microvascular occlusion are, at least in part, thrombotic events. Our new data, presented 
Win Figures 3-7 indicate that factors secreted from activated platelets, including a-granule 
Othrombospondin, promote sickle red cell adherence. Since significant adherence is observed at 
<plasma concentrations of thrombospondin (e.g. 200ng/ml, Fig 5) (8) and thrombospondin 
O. concentrations are on the order of 10mg/rn1 (e.g. 50 times higher) in serum (8), we postulate that 
z thrombospondin-mediated adherence in vivo may be very high in the presence of activated platelets. 
n Thus, our new data provide a potential link between platelet activation and microvascular occlusion 
'via adherence of sickle red cells to microvascular endothelium. This exciting hypothesis will drive 
11:1. our experiments for the next budget period. 
'4 4. Plans 
z Specific Aims #1&2.  During the next budget period, we plan to explore the following hypothesis 
related to specific aim #1: Specific plasma factors are responsible for the plasma-mediated adherence 
t to microvascular endothelium observed in Figure 2. We will identifying specific plasma factors (e.g. 
Z thrombospondin, fibrinogen, fibronectin, etc.) and endothelial cell receptors (e.g. vitronectin [a v133], 
5!CD36, etc.) which plasma factor(s) bind to by (a) quantifying the level of specific adhesion factors in 
‘'d sickle plasma for each patient, (b) depleting plasma of these factors by affinity chromatography, and 
(c) utilizing purified protein in experiments similar to those in Figure 5. Additionally, we will identify 
receptors on endothelial cells which participate in adhesion by blocking access to these receptors 
with monoclonal antibodies. These studies will be performed essentially as outlined in the funded 
application. 
Specific Aims #2&3.  A major goal of the next budget period is to further characterize the mechanism 
of ASPS and thrombospondin-mediated adherence in vitro. In addition, we will study patients in 
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crisis as well as during steady-state to determine whether ASPS or thrombospondin-mediated 
adherence correlates with patient clinical condition (e.g. crises/year, clinical severity as defined in 
the literature, etc.). We will also investigate the relationship between CD36 and the vitronectin 
receptor since antibodies to both essentially block all thrombospondin-mediated adherence. In 
addition, we will characterize the ASPS-mediated adherence not inhibited by OKM5 (Figure 4). 
This adherence could be due to other adherence proteins secreted from platelets (e.g. vWF, 
fibrinogen) or it could be due to endothelial cell stimulation by released ADP, thrombin, or seretonin. 
CI Specific Aim #4.  The endothelial agonists released from activated platelets (e.g. ADP, thrombin, or 
seretonin) along with cytokines and other vaso-active substances likely upregulate receptor 
expression of microvascular endothelium in a manner similar to that reported for large vessel 
endothelium (see 12,13, and original application for full literature review). As outlined in the 
L.°' proposal, modulation of endothelial cell receptor expression is another way to alter sickle cell 
C.) adherence. These data likely will have clinical relevance as follows. If these physiological mediators 
Z (e.g. interferon gamma) increases receptor expressimi (e.g. CD36, see ref 12) and subsequently 
f" elevate sickle cell adherence (the hypothesis we will test), then we can further postulate that in 
' vivo, infection (leading to white cell activation and cytokine secretion) could elevate sickle cell 
adherence to microvascular endothelium and precipitate vaso-occlusion. The fact that infections 
• frequently occur in conjunction with or prior to crisis (14) would appear to make testing our present 
CC hypothesis all the more relevant. 
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